RT Journal Article
SR Electronic
T1 Transcriptome and Functions of Granulocytic Myeloid-Derived Suppressor Cells Determine their Association with Disease Severity of COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.26.21254441
DO 10.1101/2021.03.26.21254441
A1 Dean, Matthew J.
A1 Ochoa, Juan B.
A1 Sanchez-Pino, Maria
A1 Zabaleta, Jovanny
A1 Garai, Jone
A1 Del Valle, Luis
A1 Wyczechowska, Dorota
A1 Buckner, Lyndsey
A1 Philbrook, Phaethon
A1 Majumder, Rinku
A1 Heide, Richard Vander
A1 Dunkenberger, Logan
A1 Thylur, Ramesh
A1 Nossaman, Robert
A1 Roberts, W. Mark
A1 Chapple, Andrew
A1 Collins, Jack
A1 Luke, Brian
A1 Johnson, Randall
A1 Koul, Hari
A1 Rees, Christopher A.
A1 Morris, Claudia R.
A1 Garcia-Diaz, Julia
A1 Ochoa, Augusto C.
YR 2021
UL http://medrxiv.org/content/early/2021/03/29/2021.03.26.21254441.abstract
AB COVID-19 ranges from asymptomatic in 35% of cases to severe in 20% of patients. Differences in the type and degree of inflammation appear to determine the severity of the disease. Recent reports show an increase in circulating monocytic-myeloid-derived suppressor cells (M-MDSC) in severe COVID 19, that deplete arginine but are not associated with respiratory complications. Our data shows that differences in the type, function and transcriptome of Granulocytic-MDSC (G-MDSC) may in part explain the severity COVID-19, in particular the association with pulmonary complications. Large infiltrates by Arginase 1+ G-MDSC (Arg+G-MDSC), expressing NOX-1 and NOX-2 (important for production of reactive oxygen species) were found in the lungs of patients who died from COVID-19 complications. Increased circulating Arg+G-MDSC depleted arginine, which impaired T cell receptor and endothelial cell function. Transcriptomic signatures of G-MDSC from patients with different stages of COVID-19, revealed that asymptomatic patients had increased expression of pathways and genes associated with type I interferon (IFN), while patients with severe COVID-19 had increased expression of genes associated with arginase production, and granulocyte degranulation and function. These results suggest that asymptomatic patients develop a protective type I IFN response, while patients with severe COVID-19 have an increased inflammatory response that depletes arginine, impairs T cell and endothelial cell function, and causes extensive pulmonary damage. Therefore, inhibition of arginase-1 and/or replenishment of arginine may be important in preventing/treating severe COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was supported by funding from LSU Health and Ochsner Medical Center. Core facilities, personnel and services partially supported by P20-GM103501, P20-CA233374 and P20-GM121288.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:LSU IRB protocol #20-053 and Ochsner Medical Center IRB protocol 21015-101CAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRelevant data is all included in the body and supplemental information.